ANAPTYSBIO, INC. — Revenue by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6822972e-df96-4383-ad7a-5060d2520615/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $234.6M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-088290 |
| FY 2024 | $91.3M | 2024-01-01 – 2024-12-31 | evidence 0001370053-25-000024 |
| FY 2023 | $17.2M | 2023-01-01 – 2023-12-31 | evidence 0001370053-24-000011 |
| FY 2022 | $10.3M | 2022-01-01 – 2022-12-31 | evidence 0001370053-23-000020 |
| FY 2021 | $63.2M | 2021-01-01 – 2021-12-31 | evidence 0001370053-22-000009 |
| FY 2020 | $75.0M | 2020-01-01 – 2020-12-31 | evidence 0001370053-21-000019 |
| FY 2019 | $8.0M | 2019-01-01 – 2019-12-31 | evidence 0001370053-20-000009 |
| FY 2018 | $5.0M | 2018-01-01 – 2018-12-31 | evidence 0001370053-20-000009 |
| FY 2017 | $10.0M | 2017-01-01 – 2017-12-31 | evidence 0001370053-20-000009 |
| FY 2016 | $16.7M | 2016-01-01 – 2016-12-31 | evidence 0001370053-19-000006 |
| FY 2015 | $17.6M | 2015-01-01 – 2015-12-31 | evidence 0001370053-18-000014 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ANAPTYSBIO, INC. — all facts · Net Income · Operating Income